Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancer

被引:51
作者
Suzuki, K
Yamamoto, M
Hasegawa, Y
Ando, M
Shima, K
Sako, C
Ito, G
Shimokata, K
机构
[1] Nagoya Univ, Grad Sch Med, Dept Med, Div Resp Dis,Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Nagoya Ekisaikai Hosp, Dept Resp Med, Nagoya, Aichi, Japan
[3] Kyoto Univ, Ctr Student Hlth, Kyoto, Japan
关键词
lung cancer; brain metastasis; staging; MRI; CT;
D O I
10.1016/j.lungcan.2004.05.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We evaluated the usefulness of double-dose (0.2 mmol/kg of gadoteridol) contrast-enhanced magnetic resonance imaging (C-E MRI) in detecting brain metastases of Lung cancer. We prospectively enrolled 134 patients with lung cancer who had no neurologic symptoms and who underwent a staging work-up. Patients were assigned to receive both contrast-enhanced computerized tomography (C-E CT) and double-dose C-E MRI. Double-dose C-E MRI detected brain metastases in 19 patients, while C-E CT detected brain metastasis in only 12 of the 19 (P = 0.02). The 3-month survival rate for patients in double-dose C-E MRI group was found to be 2.06 times that of patients in a C-E CT group (P = 0.029), although the survival rate fell to 1.45 (P = 0.387) at 6 months. The results imply that double-dose C-E MRI changed the clinical stage of Lung cancer patients. We concluded that double-dose C-E MRI improves the rate of detection of brain metastases during the initial staging of lung cancer. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:357 / 360
页数:4
相关论文
共 8 条
  • [1] Enhancement of cerebral diseases: How much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T
    Brekenfeld, C
    Foert, E
    Hundt, W
    Kenn, W
    Lodeann, KP
    Gehl, HB
    [J]. INVESTIGATIVE RADIOLOGY, 2001, 36 (05) : 266 - 275
  • [2] SPREADING EVALUATION IN PRIMITIVE BRONCHOGENIC-CARCINOMA - BENEFIT OF CEREBRAL MRI COMPARED TO CT SCAN
    LEMIERE, C
    PERETTIVITON, P
    THOMAS, P
    GAUBERT, JY
    DISTEFANOLOUINEAU, D
    KLEISBAUER, JP
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (10) : 1715 - 1715
  • [3] NOMOTO Y, 1995, JPN J CLIN ONCOL, V24, P258
  • [4] American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
    Pfister, DG
    Johnson, DH
    Azzoli, CG
    Sause, W
    Smith, TJ
    Baker, S
    Olak, J
    Stover, D
    Strawn, JR
    Turrisi, AT
    Somerfield, MR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) : 330 - 353
  • [5] MR-IMAGING DETECTION OF CEREBRAL METASTASES WITH A SINGLE INJECTION OF HIGH-DOSE GADOTERIDOL
    RUNGE, VM
    WELLS, JW
    NELSON, KL
    LINVILLE, PM
    [J]. JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1994, 4 (05): : 669 - 673
  • [6] Diagnostic accuracy of MRI compared to CCT in patients with brain metastases
    Schellinger, PD
    Meinck, HM
    Thron, A
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1999, 44 (03) : 275 - 281
  • [7] Detection of brain metastasis in potentially operable non-small cell lung cancer - A comparison of CT and MRI
    Yokoi, K
    Kamiya, N
    Matsuguma, H
    Machida, S
    Hirose, T
    Mori, K
    Tominaga, K
    [J]. CHEST, 1999, 115 (03) : 714 - 719
  • [8] YUH WTC, 1994, AM J NEURORADIOL, V15, P1037